DELFI uses artificial intelligence and whole genome sequencing to sensitively detect unique patterns of DNA fragmentation in the blood of patients with cancer.
Location: United States, Maryland, Baltimore
Employees: 11-50
Total raised: $325M
Founded date: 2019
Investors 6
| Date | Name | Website |
| - | Foresite C... | foresiteca... |
| - | Johns Hopk... | ventures.j... |
| - | Menlo Vent... | menlovc.co... |
| - | OrbiMed | orbimed.co... |
| - | INITIATE V... | initiate.v... |
| - | AV8 Ventur... | av8.vc |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 19.07.2022 | Series B | $225M | Samsara Bi... |
| 14.01.2021 | Series A | $100M | - |
Mentions in press and media 19
| Date | Title | Description |
| 08.10.2024 | New Frontiers in Lung Cancer Detection and Treatment: A Dual Approach | Lung cancer remains a formidable adversary in the battle against cancer. It is the leading cause of cancer-related deaths globally. However, recent advancements in detection and treatment offer a glimmer of hope. Two significant development... |
| 07.10.2024 | Allegheny Health Network explores use of promising new blood-based test to enhance lung cancer detection | FirstLook blood collection kit Study seeks to determine if new blood test from DELFI Diagnostics can boost earlier lung cancer diagnosis, reduce death rates PITTSBURGH, Oct. 7, 2024 /PRNewswire-PRWeb/ -- Allegheny Health Network (AHN) and D... |
| 05.06.2024 | DELFI Diagnostics Receives Equity Investment From Merck Global Health Innovation Fund | DELFI Diagnostics, a Palo Alto, CA-based developer of blood-based tests, received an equity investment from the Merck Global Health Innovation Fund (GHIF). The amount of the deal was not disclosed. The company intends to use the funds to ac... |
| 02.04.2024 | City of Hope and DELFI Diagnostics announce collaboration to improve lung cancer screening rates in underserved areas of Los Angeles | City of Hope to launch an investigator-led study funded by a grant from the American Cancer Society to improve screening among patients, including a Federally Qualified Health Center FirstLook Lung is the first liquid biopsy test available ... |
| 06.09.2022 | The 21 most promising healthtech startups of 2022, according to top VCs | Ali Ansary, the CEO of Ozette; Ashwini Zenooz, the CEO of Commure; Lucia Huang, the CEO of Osmind; and Sid Viswanathan, the CEO of Truepill. Ozette; Commure; Osmind; Truepill; Rachel Mendelson/Insider This story is available exclusively to ... |
| 19.07.2022 | Delfi Diagnostics Announces $225 Million Series B Financing to Develop Globally Accessible Portfolio of Liquid Biopsy Tests | DFJ Growth’s Justin Kao Joins Delfi Board of Directors Delfi Diagnostics, Inc., a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, announced a Series B fundin... |
| 19.07.2022 | Delfi Diagnostics raises $225M to develop lung cancer detection technology | Baltimore life sciences company Delfi Diagnostics is $225 million closer to bringing its blood test for early detection of cancer to the market. The 2021 RealLIST Startups honoree’s Series B was led by DFJ Growth with participation from Eli... |
| 19.07.2022 | Delfi Diagnostics Announces $225 Million Series B Financing to Develop Globally Accessible Portfolio of Liquid Biopsy Tests | - |
| 18.07.2022 | Delfi Diagnostics Raises $225M in Series B Financing | Delfi Diagnostics, Inc., a Palo Alto, CA- and Baltimore, MD-based developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, raised USD225m in Series B funding. This round was led... |
| 18.07.2022 | Delfi Diagnostics Announces $225M Series B | BALTIMORE, MD, Delfi Diagnostics announced a Series B funding of $225 million. >> Click here for more funding data on Delfi Diagnostics >> To export Delfi Diagnostics funding data to PDF and Excel, click here Delfi Diagno... |
Show more